Alnylam to Webcast Conference Call Discussing Third Quarter 2017 Financial Results
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics
company, announced today that it will report financial results for the
third quarter ending September 30, 2017 on Tuesday, November 7, 2017,
after the U.S. financial markets close.
Management will provide an update on the Company and discuss third
quarter 2017 results as well as expectations for the future via
conference call on Tuesday, November 7, 2017 at 4:30 p.m. ET. To access
the call, please dial 877-312-7507 (domestic) or 631-813-4828
(international) five minutes prior to the start time and refer to
conference ID 2432127. A replay of the call will be available beginning
at 7:30 p.m. ET on the day of the call. To access the replay, please
dial 855-859-2056 (domestic) or 404-537-3406 (international), and refer
to conference ID 2432127.
A live audio webcast of the call will be available on the Investors
section of the Company's website, www.alnylam.com.
An archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference
(RNAi) into a whole new class of innovative medicines with the potential
to transform the lives of people afflicted with rare genetic,
cardio-metabolic, and hepatic infectious diseases. Based on Nobel
Prize-winning science, RNAi therapeutics represent a powerful,
clinically validated approach for the treatment of a wide range of
severe and debilitating diseases. Founded in 2002, Alnylam is delivering
on a bold vision to turn scientific possibility into reality, with a
robust discovery platform and deep pipeline of investigational
medicines, including four product candidates that are in late-stage
development. Looking forward, Alnylam will continue to execute on its
"Alnylam 2020" strategy of building a multi-product, commercial-stage
biopharmaceutical company with a sustainable pipeline of RNAi-based
medicines to address the needs of patients who have limited or
inadequate treatment options. Alnylam employs over 600 people in the
U.S. and Europe and is headquartered in Cambridge, MA. For more
information about our people, science and pipeline, please visit www.alnylam.com
and engage with us on Twitter at @Alnylam
or on LinkedIn.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171030005921/en/
Alnylam Pharmaceuticals, Inc.
Investors and Media
Regan Lindenboom, 617-682-4340
Source: Alnylam Pharmaceuticals, Inc.
News Provided by Acquire Media